IDT Australia used its 2025 Annual General Meeting to update investors on its strategy reset, its return to its manufacturing roots, and its positioning at the forefront of Australia’s rapidly expanding advanced therapeutics sector.
The company said that after a period of rapid revenue growth but uneven profitability, it is now pursuing a more disciplined, margin-focused path.
Executive chair Mark Simari and fellow directors Geoffrey Sam and Dr Jane Ryan outlined the forces reshaping the global biopharmaceutical landscape, including diversified manufacturing supply chains, rising investment in Australian clinical trials, and unprecedented momentum in mRNA and radiopharmaceutical innovation.
Against this backdrop, IDT said its unique capabilities, most notably Australia’s only cGMP commercial API facility and the country’s first in-human mRNA vaccine manufacturing capability, now offer a competitive advantage that few regional players can match.
At the heart of its reset is a shift away from the 'growth at all costs' mindset that characterised recent years, the company said. Despite revenue increasing 182 per cent over the past two years to $19.9 million, the company posted a net loss of $8.1 million for the financial year 2025. This prompted a reassessment with a renewed focus on profitability, right-sizing operations, and redirecting investment toward segments showing the most substantial long-term potential.
API manufacturing, the company’s legacy business, has been formally re-established as the foundation for growth, forming the entry point for clients and creating downstream opportunities across IDT’s two other verticals, which are Specialty Orals and Advanced Therapies.
The company said its financial performance in the early financial year 2026 suggests the reset is beginning to pay off. First-quarter revenue rose 18.2 per cent year-on-year to $4.3 million, with a more balanced contribution across the three divisions.
IDT also used the AGM to highlight its growing relevance in two markets entering a period of exponential global expansion. The global mRNA therapeutics market is forecast to surpass US$21.5 billion by 2032, while the radiopharmaceuticals sector is expected to double by 2029. IDT has already produced more than 20 mRNA products and is emerging as a commercial-scale partner for radiopharmaceutical programs, positioning the company as a critical regional supplier in both fields.